GNFT vs. CLLS, XFOR, VCXB, ELEV, CGEN, OPT, ZURA, BCAB, CRDF, and ABOS
Should you be buying Genfit stock or one of its competitors? The main competitors of Genfit include Cellectis (CLLS), X4 Pharmaceuticals (XFOR), 10X Capital Venture Acquisition Corp. III (VCXB), Elevation Oncology (ELEV), Compugen (CGEN), Opthea (OPT), Zura Bio (ZURA), BioAtla (BCAB), Cardiff Oncology (CRDF), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "biological products, except diagnostic" industry.
Genfit (NASDAQ:GNFT) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
Genfit has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500.
Genfit currently has a consensus price target of $11.00, suggesting a potential upside of 189.47%. Cellectis has a consensus price target of $8.50, suggesting a potential upside of 179.61%. Given Genfit's higher possible upside, equities research analysts plainly believe Genfit is more favorable than Cellectis.
In the previous week, Genfit had 4 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Genfit and 2 mentions for Cellectis. Cellectis' average media sentiment score of 1.08 beat Genfit's score of 0.58 indicating that Cellectis is being referred to more favorably in the news media.
Genfit has higher revenue and earnings than Cellectis.
Cellectis received 340 more outperform votes than Genfit when rated by MarketBeat users. Likewise, 68.13% of users gave Cellectis an outperform vote while only 68.09% of users gave Genfit an outperform vote.
Genfit has a net margin of 0.00% compared to Cellectis' net margin of -1,087.66%. Genfit's return on equity of 0.00% beat Cellectis' return on equity.
2.2% of Genfit shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 4.2% of Genfit shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Cellectis beats Genfit on 8 of the 15 factors compared between the two stocks.
Get Genfit News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
